Session Speaker

Bradeion Project: Monitoring and Targeting of Cancer -- Successful Molecular Marker Diagnosis of Cancer by Fluorescence Correlation Spectroscopy (FCS)
Manami Tanaka, Tomoo Tanaka, Fumihiro Kimura, Kiyoshi Komori, Yukio Usui, Toshiro Terachi, Nobuhiko Yamamoto, Shinji Morimoto, Yoshinori Sakai, and Masaomi Fujiwara M.
Japan

Molecular diagnostic method has long been under investigation, but not yet succeeded to provide a solution for its promise. With the advent of current technology development in nano-scale, we have succeeded to develop the effective serum test for early diagnosis of cancer. The human Sept4/Bradeion GTPase (68Kda) is specifically expressed in colorectal cancer, prostate cancer, and other urologic cancers such as renal cell carcinoma and bladder cancer. Significance of Bradeion is that, 1) ‘all or none’ expression only in specific cancer such as colorectal adenocarcinoma and prostate cancer, 2) no genetic alterations among patients, and 3) strong tissue-and cell type-specificity. This character satisfies the desired criteria as targets to monitor and control cancer. Fluorescence correlation spectroscopy (FCS) can directly and quickly analyze protein-protein binding in a sample solution by reflecting the molecular weight of the labeled molecules. Monoclonal antibodies were successfully applied with 10 ?l patients’ serum, and the resulting diagnostic efficacy was as follows; 100% (colorectal cancer), 63.6% (prostate cancer), 90.3% (renal cell carcinoma), and 51.8% (bladder cancer). More importantly, the increased Bradeion titers became within normal level after one week (colorectal cancer) to 3 weeks (renal cell carcinoma) after surgical detection of the cancer.

1. Garcia, W.; Tanaka, M.; Tanaka, T.; Garratt, R.C.; et al. Biochimica et Biophysica Acta (BBA) – Proteins and Proteomics 2008, 1784, 1720-1727.
2. Garcia, W.; Tanaka, M.; Tanaka, T.; Garratt, R.C.; et al. Biochemistry 2007, 46, 11101-11109.
3. Garcia, W.; Hillebrand, E.; Tanaka, M.; Tanaka, T.; Garratt, R.C.; et al. Biochemistry 2006, 45, 13918-13931.
4. Hillebrand, S.; Garcia, W.; Tanaka, M.; Tanaka, T.; Garrat, R.C.; et al. Analytical and Bioanalytical Chemistry 2005, 83(1), 92-97.
5. Tanaka, M.; Tanaka, T.; et al. Medical Science Monitor, 2003, 9(7), 61-68.
6. Tanaka M.; Tanaka T.; et al. Cancer Gene Therapy 2002, 9(6), 483-488.
7. Maraca, I.G.; Tanaka, M.; Tanaka, T.; et al. Mol. Biol. Cell 2002, 13, 4111-4113.
8. Tanaka, M.; Tanaka T.; et al. Biochem. Biophy. Res. Commun. 2001, 286, 547-553.